Trial Profile
Phase II, Single-arm Study of AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3]
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Jul 2020
Price :
$35
*
At a glance
- Drugs Defosbarasertib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Acronyms SUKSES-N3
- 25 Jun 2020 Results of pooled analysis from SUKSES C, SUKSES D, SUKSES N1 and SUKSES N3 published in the Cancer.
- 04 Jun 2019 Results assessing efficacy of AZD1775, AZD2014, AZD2811 in 3 trials (NCT02593019, NCT03106155, NCT03366675), presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 23 Nov 2018 Status changed from recruiting to discontinued.